摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-amino-2-phosphoryloxymethyl-6-(4-(4-hexylphenyl)phenyl)hexanol | 845550-26-7

中文名称
——
中文别名
——
英文名称
2-amino-2-phosphoryloxymethyl-6-(4-(4-hexylphenyl)phenyl)hexanol
英文别名
[2-Amino-6-[4-(4-hexylphenyl)phenyl]-2-(hydroxymethyl)hexyl] dihydrogen phosphate
2-amino-2-phosphoryloxymethyl-6-(4-(4-hexylphenyl)phenyl)hexanol化学式
CAS
845550-26-7
化学式
C25H38NO5P
mdl
——
分子量
463.554
InChiKey
NMXLEKWPKJTDEG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    32
  • 可旋转键数:
    15
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.52
  • 拓扑面积:
    113
  • 氢给体数:
    4
  • 氢受体数:
    6

文献信息

  • [EN] SUBSTITUTED IMIDAZO[1,2-A]PYRAZINES AS MODULATORS OF KINASE ACTIVITY<br/>[FR] IMIDAZO[1,2-A]PYRAZINES SUBSTITUEES UTILISEES COMME MODULATEURS DE L'ACTIVITE D'UNE KINASE
    申请人:CELLULAR GENOMICS INC
    公开号:WO2005019220A2
    公开(公告)日:2005-03-03
    Certain substituted imidazo[1,2-a]pyrazines and the pharmaceutically-acceptable salts thereof, are provided herein. Pharmaceutical compositions containing one or more compound of Formula I, or a pharmaceutically acceptable salt of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to EphB4 kinase modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Thus methods of treatment include administering a sufficient amount of a compound of the invention to decrease the symptoms or slow the progression of these diseases or disorders. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with one or more other therapeutic agents. A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with a compound of Formula I under conditions that permit detection of activity of the angiogenic kinase, detecting a level of the activity of the angiogenic kinase, and therefrom determining the presence or absence of the angiogenic kinase in the sample.
查看更多